Cognitive Assessment in Parkinson's Disease

Parkinson’s disease is characterised not only by motor impairments but also by a spectrum of cognitive changes that may progress from subtle executive dysfunction to dementia. Early and accurate assessment of cognitive status is crucial for prognosis, tailored therapeutic strategies and patient care planning. Traditional neuropsychological batteries provide detailed cognitive profiles but are often time-consuming and resource-intensive, driving efforts to develop briefer yet reliable screening instruments. Core cognitive domains of interest include attention, executive function, memory, language and visuospatial skills. The introduction of standardised criteria for mild cognitive impairment in Parkinson’s disease (PD-MCI) and Parkinson’s disease dementia (PDD) has harmonised diagnostic thresholds, facilitating comparisons across clinical and research settings worldwide. Recent innovations encompass digital platforms, machine-learning classifiers and culturally adapted test versions, reflecting a shift towards more accessible, scalable and precise assessment approaches that support both individualised care and large-scale epidemiological studies.

Research from Nature Portfolio

A foundational study in Taiwan evaluated the Mini-Mental State Examination and the Montreal Cognitive Assessment in 168 patients with Parkinson’s disease, developing a conversion formula and a predictive model for mild cognitive impairment. By integrating delayed recall performance and visuospatial indices, the model achieved an area under the curve exceeding 0.98, indicating exceptional discrimination. This work underscores the value of combining standard cognitive screens with statistical modelling to improve early detection of cognitive decline in diverse clinical populations.

Cognitive Assessment in Parkinson's Disease publication trend

The graph below shows the total number of articles in cognitive assessment in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Mini-Mental State Examination (MMSE): A brief questionnaire assessing orientation, recall, attention and language to screen for cognitive impairment.

Montreal Cognitive Assessment (MoCA): A 30-point test designed to detect mild cognitive deficits across multiple domains including executive and visuospatial functions.

Mild Cognitive Impairment in Parkinson’s Disease (PD-MCI): A stage of cognitive decline greater than expected for age and education but not significantly interfering with daily activities.

Parkinson’s Disease Dementia (PDD): The onset of dementia in the context of established Parkinson’s disease motor symptoms, marked by marked decline in multiple cognitive domains.

Receiver Operating Characteristic (ROC) curve: A plot showing the balance between sensitivity and specificity for a screening test across various threshold values.

References

1. Outcome of visuospatial dysfunction assessment in patients with Parkinson’s disease using mobile application software. Frontiers in Aging Neuroscience (2023).
2. Evaluating Mild Cognitive Dysfunction in Patients with Parkinson’s Disease in Clinical Practice in Taiwan. Scientific Reports (2020).
3. Validity and diagnostics of the Italian version of the Montreal Cognitive Assessment (MoCA) in non-demented Parkinson’s disease patients. Aging Clinical and Experimental Research (2023).
4. Optimization of cognitive assessment in Parkinsonisms by applying artificial intelligence to a comprehensive screening test. npj Parkinson's Disease (2022).